FIGURE 1.

The effect of lmwCAFS and MT‐lmwCAFS on PC‐3 cells. (A) The workflow for collecting high molecular weight and low molecular weight secretome of prostate CAFs untreated/treated with MPSSS. (B) PC‐3 cells were exposed to CM⁰, CM^0.2, CM^0.4, CM^0.6, CM^0.8, and CM^1.0 and fresh DMEM (v/v = 1:1) for 24 h. n = 4 biological replicates, ***p ≤ 0.001: PC‐3 cells treated with CM^0.2, CM^0.4, CM^0.6, CM^0.8, and CM^1.0 compared with PC‐3 cells treated with CM⁰, respectively. (C) PC‐3 cells were exposed to lmwCAFS and MT‐lmwCAFS (3‐ to 100‐kD secretome) with final protein concentrations of 50, 100, 150, and 200 μg/ml for 24 h. n = 4 biological replicates, ns and ***p ≤ 0.001: PC‐3 cells treated with MT‐lmwCAFS compared with PC‐3 cells treated with lmwCAFS. ^{^^^} p ≤0.001: PC‐3 cells treated with lmwCAFS. °p ≤0.001: PC‐3 cells treated with MT‐lmwCAFS. (D) PC‐3 cells were exposed to hmwCAFS and MT‐hmwCAFS (>100‐kD secretome) at final protein concentrations of 50, 100, 150, and 200 μg/ml for 24 h